+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Hepatocellular Carcinoma Drugs Market 2020-2024- Product Image

Global Hepatocellular Carcinoma Drugs Market 2020-2024

  • ID: 5130930
  • Report
  • July 2020
  • Region: Global
  • 120 pages
  • TechNavio

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
Global Hepatocellular Carcinoma Drugs Market 2020-2024

The hepatocellular carcinoma drugs market is poised to grow by $ 85.10 mn during 2020-2024 progressing at a CAGR of 3% during the forecast period. The report on the hepatocellular carcinoma drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of liver diseases and lifestyle diseases.

The hepatocellular carcinoma drugs market analysis includes the rapy segment and geographic landscape.

The hepatocellular carcinoma drugs market is segmented as below:

By Therapy
  • Chemotherapy
  • Brachytherapy
  • Ablation therapy
By Geographic Landscapes
  • North America
  • Europe
  • APAC
  • ROW
This study identifies increasing product launches as one of the prime reasons driving the hepatocellular carcinoma drug market growth during the next few years.

This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. The hepatocellular carcinoma drugs market covers the following areas:
  • Hepatocellular carcinoma drugs market sizing
  • Hepatocellular carcinoma drugs market forecast
  • Hepatocellular carcinoma drugs market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading hepatocellular carcinoma drugs market vendors that include AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Johnson & Johnson, and Pfizer Inc. Also, the hepatocellular carcinoma drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. This market research report provides a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
Executive Summary
  • Market Overview
Market Landscape
  • Market ecosystem
  • Value chain analysis
Market Sizing
  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024
Five Forces Analysis
  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
Market Segmentation by Therapy
  • Market segments
  • Comparison by Therapy
  • Chemotherapy - Market size and forecast 2019-2024
  • Brachytherapy - Market size and forecast 2019-2024
  • Ablation therapy - Market size and forecast 2019-2024
  • Market opportunity by Therapy
Customer landscape

Geographic Landscape
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • APAC - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends
Vendor Landscape
  • Vendor landscape
  • Landscape disruption
Vendor Analysis
  • Vendors covered
  • Market positioning of vendors
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • Johnson & Johnson
  • Pfizer Inc.
Appendix
  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations
List of Exhibits
1: Key Finding 1
2: Key Finding 2
3: Key Finding 3
4: Key Finding 5
5: Key Finding 6
6: Key Finding 7
7: Key Finding 8
8: Parent market
9: Market characteristics
10: Offerings of vendors included in the market definition
11: Market segments
12: Global - Market size and forecast 2019 - 2024 ($ million)
13: Global market: Year-over-year growth 2019 - 2024 (%)
14: Five forces analysis 2019 & 2024
15: Bargaining power of buyers
16: Bargaining power of suppliers
17: Threat of new entrants
18: Threat of substitutes
19: Threat of rivalry
20: Market condition - Five forces 2019
21: Other1 - Market share 2019-2024 (%)
22: Comparison by Other1
23: Chemotherapy - Market size and forecast 2019-2024 ($ million)
24: Chemotherapy - Year-over-year growth 2019-2024 (%)
25: Brachytherapy - Market size and forecast 2019-2024 ($ million)
26: Brachytherapy - Year-over-year growth 2019-2024 (%)
27: Ablation therapy - Market size and forecast 2019-2024 ($ million)
28: Ablation therapy - Year-over-year growth 2019-2024 (%)
29: Market opportunity by Other1
30: Customer landscape
31: Market share by geography 2019-2024 (%)
32: Geographic comparison
33: North America - Market size and forecast 2019-2024 ($ million)
34: North America - Year-over-year growth 2019-2024 (%)
35: Europe - Market size and forecast 2019-2024 ($ million)
36: Europe - Year-over-year growth 2019-2024 (%)
37: APAC - Market size and forecast 2019-2024 ($ million)
38: APAC - Year-over-year growth 2019-2024 (%)
39: ROW - Market size and forecast 2019-2024 ($ million)
40: ROW - Year-over-year growth 2019-2024 (%)
41: Key leading countries
42: Market opportunity by geography ($ million)
43: Impact of drivers and challenges
44: Vendor landscape
45: Landscape disruption
46: Industry risks
47: Vendors covered
48: Market positioning of vendors
49: AbbVie Inc. - Overview
50: AbbVie Inc. - Business segments
51: AbbVie Inc. - Key offerings
52: AbbVie Inc. - Key customers
53: AbbVie Inc. - Segment focus
54: Amgen Inc. - Overview
55: Amgen Inc. - Business segments
56: Amgen Inc. - Key offerings
57: Amgen Inc. - Key customers
58: Amgen Inc. - Segment focus
59: AstraZeneca Plc - Overview
60: AstraZeneca Plc - Product and service
61: AstraZeneca Plc - Key offerings
62: AstraZeneca Plc - Key customers
63: AstraZeneca Plc - Segment focus
64: Bayer AG - Overview
65: Bayer AG - Business segments
66: Bayer AG - Key offerings
67: Bayer AG - Key customers
68: Bayer AG - Segment focus
69: Bristol-Myers Squibb Co. - Overview
70: Bristol-Myers Squibb Co. - Product and service
71: Bristol-Myers Squibb Co. - Key offerings
72: Bristol-Myers Squibb Co. - Key customers
73: Bristol-Myers Squibb Co. - Segment focus
74: Eli Lilly and Co. - Overview
75: Eli Lilly and Co. - Business segments
76: Eli Lilly and Co. - Key offerings
77: Eli Lilly and Co. - Key customers
78: Eli Lilly and Co. - Segment focus
79: F. Hoffmann-La Roche Ltd. - Overview
80: F. Hoffmann-La Roche Ltd. - Business segments
81: F. Hoffmann-La Roche Ltd. - Key offerings
82: F. Hoffmann-La Roche Ltd. - Key customers
83: F. Hoffmann-La Roche Ltd. - Segment focus
84: Gilead Sciences Inc. - Overview
85: Gilead Sciences Inc. - Product and service
86: Gilead Sciences Inc. - Key offerings
87: Gilead Sciences Inc. - Key customers
88: Gilead Sciences Inc. - Segment focus
89: Johnson & Johnson - Overview
90: Johnson & Johnson - Business segments
91: Johnson & Johnson - Key offerings
92: Johnson & Johnson - Key customers
93: Johnson & Johnson - Segment focus
94: Pfizer Inc. - Overview
95: Pfizer Inc. - Business segments
96: Pfizer Inc. - Key offerings
97: Pfizer Inc. - Key customers
98: Pfizer Inc. - Segment focus
99: Currency conversion rates for US$
100: Research Methodology
101: Validation techniques employed for market sizing
102: Information sources
103: List of abbreviations
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
The publisher recognizes the following companies as the key players in the global hepatocellular carcinoma drugs market: AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Johnson & Johnson, and Pfizer Inc..

Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increasing product launches."

According to the report, one of the major drivers for this market is the increasing prevalence of liver diseases.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • Johnson & Johnson
  • Pfizer Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll